BioCryst (BO1) Financial Statements

1 Followers

BioCryst Financial Overview

BioCryst's market cap is currently CHF2.06B. The company's EPS TTM is CHF-1.4386; its P/E ratio is -6.92; BioCryst is scheduled to report earnings on August 5, 2026, and the estimated EPS forecast is CHF0.07. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Income Statement
Total Revenue	$ 874.84M	$ 450.71M	$ 331.41M	$ 270.83M	$ 157.17M
Gross Profit	$ 855.76M	$ 438.23M	$ 326.75M	$ 264.23M	$ 149.91M
Operating Income	$ 340.99M	$ -2.54M	$ -103.71M	$ -148.44M	$ -177.72M
EBITDA	$ 347.65M	$ 12.81M	$ -116.33M	$ -143.85M	$ -121.74M
Net Income	$ 263.86M	$ -88.88M	$ -226.54M	$ -247.12M	$ -184.06M
Balance Sheet
Cash & Short-Term Investments	$ 274.75M	$ 321.06M	$ 388.99M	$ 424.31M	$ 507.60M
Total Assets	$ 514.16M	$ 490.42M	$ 516.96M	$ 550.00M	$ 588.15M
Total Debt	$ 438.87M	$ 841.42M	$ 825.15M	$ 741.45M	$ 593.24M
Net Debt	$ 349.14M	$ 736.50M	$ 714.50M	$ 436.69M	$ 88.85M
Total Liabilities	$ 633.31M	$ 966.35M	$ 972.49M	$ 844.60M	$ 695.14M
Stockholders' Equity	$ -119.15M	$ -475.93M	$ -455.53M	$ -294.60M	$ -106.99M
Cash Flow
Free Cash Flow	$ 327.41M	$ -53.14M	$ -97.31M	$ -163.20M	$ -144.54M
Operating Cash Flow	$ 329.88M	$ -52.02M	$ -95.14M	$ -161.85M	$ -142.16M
Investing Cash Flow	$ -13.69M	$ 52.59M	$ -131.50M	$ -128.24M	$ 15.80M
Financing Cash Flow	$ -332.44M	$ -5.76M	$ 32.48M	$ 88.03M	$ 359.67M

Currency in USD

BioCryst Earnings and Revenue History

Income Statement >

BioCryst Debt to Assets

Balance Sheet >

BioCryst Cash Flow

Cash Flow >

BioCryst Forecast EPS vs Actual EPS

Earnings >